Guillain-Barre Syndrome (GBS) is an acute autoimmune disorder where the immune system mistakenly attacks peripheral nerves, leading to muscle weakness, numbness, and, in severe cases, paralysis. It typically develops after viral or bacterial infections, triggering an inflammatory response that damages myelin or axons. Although rare, GBS is a neurological emergency requiring early diagnosis and prompt treatment.

The Guillain-Barre Syndrome session explores the pathogenesis, clinical spectrum, and management of GBS and its variants, including Miller Fisher and acute motor axonal neuropathy. Researchers discuss immune mechanisms, molecular mimicry, and the role of infection-induced antibodies in peripheral nerve demyelination.

At the Guillain-Barre Conference, neurologists, immunologists, and critical-care specialists present case studies, emerging biomarkers, and therapeutic advances. Topics include electrophysiological diagnostics, CSF analysis, and the use of immunotherapies such as intravenous immunoglobulin (IVIg) and plasma exchange. Early rehabilitation approaches, prognostic scoring, and long-term functional outcomes are also highlighted.

This session welcomes clinicians and researchers focused on peripheral nerve disorders and neuroimmunology. The goal is to enhance awareness, promote standardized care pathways, and explore new therapeutic molecules that accelerate recovery.

Current discoveries in Neuroimmunopathology are unveiling novel immune signatures, aiding in differentiating GBS subtypes and guiding precision-based immunomodulation strategies.